A New Era of Medical Asset Digitization
HONG KONG SAR - Media OutReach Newswire - 21 July 2025. IVD Medical Holding Limited, with stock ticker (01931.HK), has embarked on an ambitious journey to redefine digital finance and medical innovation. As a pioneer in the space, the company has officially launched its application for a US stablecoin license and is advancing the groundbreaking IVDNewCo Exchange ecosystem. This strategy aims to establish a new global infrastructure for medical innovative drug assets.
Harnessing Global Regulatory Synergies
On 18 July 2025, US President Trump signed the “Genius Act,” granting stablecoins the status of digital dollars. This legislation, synchronized with the Hong Kong Stablecoin Ordinance, provides a harmonious regulatory framework and builds a compliance cornerstone for the global stablecoin market. According to The Manila Times, IVD Medical strategically applied for the US stablecoin license, positioning itself as a leader among Hong Kong-listed companies with a robust “Hong Kong + US” compliance infrastructure.
Technological Innovations at the Core
The IVDNewCo Exchange ecosystem centers around technological prowess—the seamless fusion of Web3 technology with medical innovative drug assets. The ecosystem facilitates asset tokenization, transforming innovative medical discoveries into tradable digital certificates. This transition overcomes liquidity barriers of traditional medical assets, paving the way for dynamic financial infrastructure supporting IVDD stablecoins.
Creating New Paradigms in Medical Finance
IVD Medical is setting a new standard in medical finance through its strategic framework of “regulatory compliance-technological innovation-ecological synergy.” By aligning with the Genius Act and Hong Kong’s legislation, the company ensures robust security and transparency. The RWA platform revolutionizes how clinical-stage pharmaceutical assets are monetized, allowing global investors to partake in medical innovation once exclusive to institutional investors.
Industry Impact and Strategic Outlook
The capital market and medical industry have taken significant notice of IVD Medical’s strategic advancements. Following the latest announcements, the company’s share price witnessed a substantial leap, reflecting investor confidence in the visionary “NewCo+RWA+stablecoin” model. Looking forward, IVD Medical plans to harness Web3 technologies, bridging the gap between traditional medical finance and digital innovations, amplifying value for patients, pharmaceutical companies, and investors alike.
Embrace a transformative future where digital finance meets medical innovation, as IVD Medical Holding Limited pushes the boundaries of what’s possible in the world of healthcare investments.
